Zobrazeno 1 - 10
of 37
pro vyhledávání: '"59"'
Autor:
Hyo S. Han, Bruce A. Bach, Shannon Puhalla, David Maag, Hans Wildiers, Véronique Diéras, Dai Feng, Jean-Pierre M. Ayoub, Christine K. Ratajczak, Michael Friedlander, Bella Kaufman, Banu Arun
Publikováno v:
Cancer Research. 81:PS11-03
Background: Veliparib (Vel) is a potent PARP1/2 inhibitor with demonstrated antitumor activity when administered alone or combined with carboplatin and paclitaxel (C/P). The phase 3 randomized, double-blind, multicenter BROCADE3 study (NCT02163694) e
Autor:
Chunqiao Tian, Z Ding, S Huang, Shara D. Rice, Paul R. Ervin, Dakun Wang, Michael J. Gabrin, David A. Gingrich, Stacey L. Brower, Kui Shen, Nan Song
Publikováno v:
Cancer Research. 70:P3-08
Background: Responses of breast cancer patients to chemotherapy treatments vary considerably, and population treatment response rates remain low. To improve patient outcomes, genomic profiles have been used to identify patients who would benefit from
Autor:
Jeffrey M. Switchenko, Christopher R. Flowers, Minal Surati, Katherine S. Shah, Jonathon B. Cohen, Christine C. Davis, Elyse Hall Panjic, Caitlin Handler, Kelly Valla, Don Hutcherson
Publikováno v:
Clinical lymphoma, myelomaleukemia. 15(5)
Although diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab and anthracycline-based therapy, within the elderly population there are additional factors to consider in selecting a treatment regimen including comorbid conditions, decreas
Publikováno v:
Clinical Breast Cancer. 21:e471-e478
Male breast cancer (MBC) comprises1% of all cancers and continues to rise. Because of rarity, there is paucity in the literature; therefore, management of MBC is generalized from female breast cancer (FBC).Data from 152 VA Medical Centers were used t
Autor:
Louise Maumy, Paul Cottu, Delphine Hequet, Jean-Marc Guinebretière, David Gentien, Céline Callens, Ivan Bièche, Anne Vincent-Salomon, Roman Rouzier, Florence Lerebours
Publikováno v:
Cancer Research. 80:P2-08
Prosigna® tests are performed in Institut Curie to guide adjuvant chemotherapy decision in early estrogen receptor (ER) positive, Human Epidermal growth factor Receptor (HER2) negative breast cancer (BC) patients, with an intermediate risk of recurr
Autor:
Sara Reis, Intan Hamid, Sophie McGrath, Susannah Stanway, Alicia Okines, Jaishree Bhosle, Vasileios Angelis, Marco Gerlinger, Heba Soliman, Zayd Tippu, Firza Gronthoud, Robin L. Jones, Emma Cottier, Charlotte Fribbens, Jillian Noble, David Watkins, Spyridon Gennatas, Kroopa Joshi, Pablo Nenclares, Kevin J. Harrington
Publikováno v:
European Journal of Cancer
Background In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted.
Publikováno v:
Leukemia Research. 109:106643
Acute lymphoblastic leukemia (ALL) is one of the most frequent hematological malignancies in children, representing approximately 25 % of all pediatric cancers. Despite striking advances in ALL treatments, a small population of patients does not stil
Autor:
Xia Song, Xin Zhang, Zhuang Yu, Lu Lu Yang, Dian-Sheng Zhong, Ping Yu, Ping hai Zhang, Qing Zhou, Qiang Shi, Yong Song, Yi-Long Wu, Guosheng Feng, Yi Hu, Jianhua Chen, Gongyan Chen, Yiping Zhang
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017)
BMC Cancer
BMC Cancer
Background In recent years, systemic chemotherapy and molecular targeted therapy have become standard first-line treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). The objective of this survey was to investi
Publikováno v:
Cancer Research. 76:P6-12
Background: Timely detection and treatment of breast cancer patients is important in survival and recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined the time to diagnosis and treatment in a safety net h
Publikováno v:
Cancer Research. 75:P4-11
Background: Breast cancer patients commonly present in locally advanced stage (LABC) in our country .We propose to correlate the pathological response to neoadjuvant chemotherapy (NACT) and its impact on survival based on the intrinsic subtype of bre